BRAF and melanoma: In this economic evaluation, adding atezolizumab to vemurafenib plus cobimetinib was associated with survival and quality-of-life improvement but was not cost-effective at a WTP value of $150 000 per QALY over a lifetime horizon compared with vemurafenib plus cobimetinib alone for patients with newly diagnosed advanced or metastatic BRAF variation melanoma from a US health care perspective.